Wilson disease is an inherited, treatable disorder of copper handling caused by disease-causing changes affecting both copies of ATP7B. Diagnosis brings together clinical findings, copper studies and genetic evidence. A low blood copper result does not automatically exclude copper accumulation in tissues, and an uncertain ATP7B variant is not, by itself, a diagnosis.
Why copper can accumulate
The ATP7B protein helps move copper into bile for removal and helps incorporate copper into ceruloplasmin, a copper-carrying protein. Impaired function can lead to copper accumulation, affecting the liver, brain and other organs. People may first come to attention through liver abnormalities, movement difficulties or neuropsychiatric changes. These symptoms have other possible causes, so the pattern needs specialist assessment. NHS Genomics Education overview.
Copper is necessary for normal biology. Wilson disease concerns its handling and accumulation, not a rule that copper is inherently harmful or that someone should eliminate it from their diet without medical guidance.
Why one copper result cannot tell the whole story
Blood, urine and tissue measurements describe different parts of copper metabolism. NIDDK notes that total blood copper can be low in Wilson disease, despite excess tissue copper; acute liver failure can instead produce high blood copper. Ceruloplasmin is often low but is not invariably low. Results should therefore be interpreted together rather than using one normal or abnormal value as a verdict. NIDDK diagnostic explanation.
| Evidence | What it contributes | What needs context |
|---|---|---|
| Ceruloplasmin and blood copper | Information about circulating copper and its carrier | A single result is not a direct inventory of all tissue copper |
| 24-hour urine copper | Copper excretion over the collection period | Collection quality and whether treatment has started |
| Clinical, liver and eye assessment | Evidence of organ involvement and alternative explanations | No single symptom is specific to Wilson disease |
| ATP7B analysis | Evidence for an inherited cause and family testing | Variant classification, allele arrangement and assay coverage |
The 2025 EASL-ERN guideline integrates clinical, biochemical and molecular findings. It also discusses relative exchangeable copper where available and liver copper quantification when required. A diagnostic score can organise evidence, but its inputs still need careful interpretation. This is a specialist process, not a self-diagnosis exercise using an isolated internet cutoff. EASL-ERN clinical practice guideline.
Read the ATP7B result at the allele level
In the usual recessive mechanism, the relevant pathogenic or likely pathogenic findings affect both gene copies. Two reported variants need not automatically mean two affected copies: they may be on the same copy, or one may have uncertain significance. GeneReviews distinguishes established biallelic pathogenic findings from combinations that remain inconclusive. A VUS does not independently establish or rule out Wilson disease. GeneReviews: Wilson disease.
If testing finds one relevant variant, ask whether the method covered other variant classes, including deletions and duplications where appropriate. Clinical and biochemical assessment should continue when the molecular result does not resolve the question. Our VUS guide explains how uncertainty differs from a negative result.
Four practical examples
Fictional example: “My blood copper is low, so this cannot be overload.” Amir has abnormal liver tests and low total blood copper. His clinician explains that the blood measurement is only one compartment and reviews ceruloplasmin, urine copper and the rest of the assessment. The next step is to reconcile the findings, not to start copper supplements based on that one number.
Fictional example: two lines on the genetic report. A report lists one pathogenic ATP7B variant and one VUS. The family assumes the diagnosis has been genetically confirmed. The team checks the evidence for the VUS, whether the variants are on different copies, and the clinical findings. The uncertainty is recorded clearly rather than hidden behind “two mutations found.”
Fictional example: an apparently well sibling. A person’s sister feels healthy after Wilson disease is diagnosed in the family. She asks whether symptoms must appear before testing is worthwhile. The clinician explains that relatives can be assessed before symptoms, using the familial findings and appropriate clinical tests. A reassuring initial blood result does not necessarily settle inherited status. NHS family-assessment guidance.
Fictional example: an incomplete urine collection. A patient misses several samples during a 24-hour collection. They tell the team rather than presenting the result as a complete day’s measurement. The clinician decides whether a repeat is needed and checks the collection instructions. Accurate information about the specimen is part of the diagnostic evidence.
What family testing can clarify
When both parents carry a pathogenic allele, each pregnancy independently has a one-in-four chance of inheriting both. That probability describes inheritance, not the timing or severity of symptoms. Identifying the familial variants can make testing relatives more focused. The exact test should follow the confirmed family result rather than a broad consumer report or a test for only one common variant. GeneReviews counselling and testing framework.
Diagnosis and ongoing monitoring ask different questions
Once a diagnosis is established, follow-up assesses organ health, treatment response, adherence and treatment safety. Copper measurements obtained during therapy are interpreted differently from untreated diagnostic samples. The EASL-ERN guideline emphasises clinical and laboratory monitoring together; this guide does not provide drug doses or instructions to change treatment. Acute liver failure requires urgent specialist care and should not wait for completion of genetic testing. 2025 management guidance.
Questions to bring to the appointment
- Which findings support the diagnosis, and which remain uncertain?
- Were the copper tests taken before or during treatment?
- Was the urine collection complete and performed as instructed?
- Which ATP7B variants were found, and is their phase known?
- What did the assay cover or leave unresolved?
- Which relatives should be offered assessment, and who coordinates it?
The family-testing guide, variant worksheet and care directory can help organise the next conversation.